ClinicalTrials.gg
RecruitingNCT06128928REDESUpdated Nov 16, 2026

Connecting Friends and Health Workers to Boost COVID-19 Vaccination in Latino Communities

An interventional study of REDES and Control in COVID-19 and Vaccine, sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jul 2023, registered Nov 2023).
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in COVID-19 by Johns Hopkins University — 2 open to participants now, 2 under way, none of them phase 3. COVID-19 · Johns Hopkins University.

Planned enrollment
2nd of 13
900 · median 35
Started
2023
the only one that year
No phase
5 of 19
1 open now
Registered
19th of 19
by date

Among the 19 studies in COVID-19 by Johns Hopkins University, this one is the 2nd largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2023, is one of 5 with no phase, and was the 19th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

2 of the 19 studies in COVID-19 by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in COVID-19 by Johns Hopkins University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to find out which approach works better in getting more of the friends and connections of Latino adults get vaccinated against COVID-19.

The main questions this study aims to answer are:

  1. Can teaching people to use motivational interviewing help more friends and connections of Latino adults get the COVID-19 vaccine compared to just giving information about the vaccine?
  2. What are the things that make it easier or harder for Latinos and networks to get the COVID-19 vaccine?
  3. How does this intervention work in practice so that it can be made available to more people in the future

The researchers will compare the vaccine rates of the friends and connections of Latinos who have been trained in motivational interviewing with those who have only been given information about the COVID-19 vaccine. This will help figure out which method works best to encourage more people to get vaccinated.

Read the detailed description

This study will test the efficacy of an intervention REDES ("Networks") - a social network intervention - to address COVID-19 vaccine hesitancy and uptake among a cohort of Latinos and networks. 300 index participants who have taken the COVID-19 vaccine will be recruited. Half of the index participants (n=150) will be randomized to the experimental group and will receive training on motivational interviewing to promote vaccine acceptance and uptake with networks. Index participants in the control group (n=150) will receive updated information about the COVID-19 vaccine. In addition, unvaccinated primary and secondary network members of indexes will be recruited for study participation and COVID-19 vaccination. All participants will be followed prospectively at 6, 12, and 18 months after baseline intake. The specific aims are: 1) Evaluate the efficacy of the REDES intervention to promote COVID-19 vaccine uptake among Latinos; 2) Examine ongoing barriers and facilitators of vaccine uptake among Latinos and networks to tailor the intervention and address new challenges, and 3) Evaluate the implementation determinants and outcomes of REDES to inform future broad-scale implementation.

03

Conditions studied

  • COVID-19
  • Vaccine

Keywords

  • COVID-19 vaccine uptake
  • Latino
  • vaccine hesitancy
  • Network referrals
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Eligibility criteria for index participants (eligibility for index participants is intended to select participants who are less vaccine hesitant):

  • Age 18 years or older, and
  • Self-identifies as Hispanic/Latino, and
  • Living in Maryland, and
  • Has received at least one COVID-19 vaccine/booster in the last 12 months.

Eligibility criteria for primary and secondary network members (peers):

Eligibility for peers is intended to select for participants who are more vaccine hesitant (e.g. unvaccinated, or have not received at least one COVID-19 vaccine/booster in the last 12 months)

  • 18 years old or older, and
  • Self-identifies as Hispanic/Latino, and
  • Living in Maryland, and
  • Provide a study coupon to verify that they were referred by an index or a primary network member, and
  • Has not received at least one COVID-19 vaccine/booster in the last 12 months.

Exclusion criteria

Exclusion Criteria:

  • Previously participated in the study
  • Lacks capacity to consent
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
900 participants (estimated)

Study arms

  • Experimental
    REDES: Motivational interviewing training

    Participants in this arm will receive training on motivational interviewing (MI) to promote vaccine acceptance and uptake with their networks. The training will be led by community health workers on how to use MI to address vaccine hesitancy using a guiding approach, open-ended questions, affirmations, reflections, and summaries.

    Behavioral: REDES

  • Active comparator
    Control: COVID-19 vaccine information

    Participants in the control condition will receive a brief community health worker-led training about the safety and efficacy of the vaccine. Participants will have the opportunity to ask clarifying questions from the community health workers during the training.

    Behavioral: Control

Interventions

  • BehavioralREDES

    Training on motivational interviewing (MI) led by community health workers on how to use MI to address vaccine hesitancy using a guiding approach, open-ended questions, affirmations, reflections, and summaries.

  • BehavioralControl

    Brief CHW-led training about the safety and efficacy of the COVID-19 vaccine. Participants will have the opportunity to ask clarifying questions from the CHWs during the training.

06

What researchers measure

Primary outcomes

  1. COVID-19 vaccine status among networks

    Number of network participants who receive the COVID-19 vaccine

    Time frame: Up to 18 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Dec 2026, 41 months after the start.

Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 41 months is above that.

Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2023
First posted
Nov 13, 2023
StartActual
Jul 8, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06128928
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Jul 8, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 16, 2026

Study contacts

Kathleen R Page, MD
Contact
kpage2@jhmi.edu
(410) 321-0909
Adrianna Moore, MSW
Contact
adrianna.moore@jhmi.edu
410-321-0909
Kathleen R Page, MD
principal investigator · Johns Hopkins University
Cui Yang, PhD
principal investigator · Rutgers University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion